Innate Pharma (IPHYF) 12.6500 $IPHYF INNATE PHARMA :

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Innate Pharma (IPHYF) 12.6500 $IPHYF

INNATE PHARMA : raises [Eur]20.3 million in a private placement subscribed entirely by US-based specialist investors
GlobeNewswire - Wed Nov 20, 1:23AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces today the completion of a private placement directed to US-based specialist institutional investors.

INNATE PHARMA : raises EUR20.3 million in a private placement subscribed entirely by US-based specialist investors
Thomson Reuters ONE - Wed Nov 20, 1:02AM CST
Marseille, November 20, 2013

Cutaneous T-Cell Lymphoma Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/n6q727/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013" report to their offering. 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Scope - A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma. - A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Seattle Genetics, Inc. - Emergent BioSolutions Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Galderma S.A. - Onyx Pharmaceuticals, Inc. - Mundipharma International Limited - Innate Pharma SA - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - Mondobiotech Holding AG - Yaupon Therapeutics, Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/n6...eous_tcell

Septic Shock - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Septic Shock
M2 - Tue Nov 05, 9:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/zm4r8p/septic_shock) has announced the addition of the "Septic Shock - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Septic Shock - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Septic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Septic Shock. Septic Shock - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Septic Shock. - A review of the Septic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Septic Shock pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Baxter International Inc. - Ferring Pharmaceuticals, Inc. - Innate Pharma SA - Lixte Biotechnology Holdings, Inc. - Medinox, Inc. - NOXXON Pharma AG - Novo Nordisk A/S - Takeda Pharmaceutical Company Limited - biosyn Arzneimittel GmbH For more information visit http://www.researchandmarkets.com/research/zm...ptic_shock About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

INNATE PHARMA : announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
GlobeNewswire - Tue Sep 17, 1:34AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB") completed its first assessment of the EffiKIR study and unanimously recommended continuation of the trial without modification.

Cutaneous T-Cell Lymphoma - Latest Pipeline Review Report
M2 - Fri Jul 12, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q8vtbk/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012" report to their offering. 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Scope - A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma. - A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipel

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbrmql/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013" report to their offering. "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication th

Sezary Syndrome - Pipeline Review, H1 2013 Contains Latest News and Deals Relating to the Products
M2 - Fri Jun 07, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2npr37/sezary_syndrome) has announced the addition of the "Sezary Syndrome - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sezary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sezary Syndrome. Sezary Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Sezary Syndrom
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 468

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 446

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Luxurious Mark Lane Apartments in Naples, FL

Updated Category News Views 205

Explore the Luxurious Mark Lane Apartments Mark Lane Apartments is a remarkable new residential community that has quickly established itself in the real estate market. A Class A+ Trophy Asset This impressive four-story concrete block building is a true trophy asset, featuring 286 spacious units, each averaging 1,050 square feet. The complex is situated on a generous...

Continue Reading
Major Revenue Surge: POP Culture Group's Impressive FY2025 Results

Updated Category News Views 226

POP Culture Group Achieves Record Revenue in FY2025 In a remarkable financial breakthrough, POP Culture Group Co., Ltd. (Nasdaq: CPOP) has announced its fiscal year 2025 results, showcasing an incredible revenue surge that exceeded $100 million for the first time. This milestone represents a significant leap, with revenue increasing by 127% compared to the previous fiscal...

Continue Reading
Jericho Wholesale and Shell Unite for Breast Cancer Awareness

Updated Category News Views 184

Jericho Wholesale and Shell Join Forces for a Cause Jericho Wholesale is proud to partner with Shell in the initiative Power Up for Pink Aid this October during Breast Cancer Awareness Month. This exciting campaign aims to assist underserved breast cancer patients and their families through vital financial support while raising awareness for the disease. What is Power Up...

Continue Reading
PMGC Holdings Implements Strategic Reverse Stock Split for Growth

Updated Category News Views 119

PMGC Holdings Announces Reverse Stock Split PMGC Holdings Inc. (NASDAQ: ELAB), based in Newport Beach, California, has recently unveiled an important strategic decision to carry out a 1-for-7 reverse stock split effective soon. This move reflects the company’s commitment to maintaining its compliance with Nasdaq’s listing requirements, which is essential for...

Continue Reading
Lynch Carpenter Takes Action on Anne Arundel Data Incident

Updated Category News Views 270

Lynch Carpenter's Response to the Data Breach Incident Recently, a cybersecurity incident was reported by Anne Arundel Dermatology, revealing that a significant breach of personal data has occurred. This disturbing event is said to have affected the personal information of numerous individuals, raising substantial concerns about data privacy. Details of the Cybersecurity...

Continue Reading